CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 254 filers reported holding CRISPR THERAPEUTICS AG in Q4 2019. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $10,000 | -64.3% | 170 | -61.8% | 0.00% | -100.0% |
| Q1 2022 | $28,000 | +115.4% | 445 | +161.8% | 0.00% | 0.0% |
| Q4 2021 | $13,000 | -77.7% | 170 | -67.3% | 0.00% | -50.0% |
| Q3 2021 | $58,204 | -24.9% | 520 | +8.6% | 0.00% | -50.0% |
| Q2 2021 | $77,545 | +288.1% | 479 | +192.1% | 0.00% | +300.0% |
| Q1 2021 | $19,983 | +226.3% | 164 | +310.0% | 0.00% | – |
| Q4 2020 | $6,124 | +57.1% | 40 | -37.5% | 0.00% | – |
| Q4 2019 | $3,898 | +48.6% | 64 | 0.0% | 0.00% | – |
| Q3 2019 | $2,623 | -13.0% | 64 | 0.0% | 0.00% | – |
| Q2 2019 | $3,014 | -71.9% | 64 | -89.3% | 0.00% | -100.0% |
| Q3 2017 | $10,722 | – | 600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |